Vilin Bio Med operating cash flow turns negative in September half
Key highlights
- Vilin Bio Med used Rs 68.10 lakh in operating cash in the half-year ended September 30, 2026.
- Inventory and trade receivables absorbed a combined Rs 603.41 lakh of cash during the half-year.
- Cash and cash equivalents fell to Rs 21.52 lakh at September 30, 2026 from Rs 146.99 lakh at March 31, 2026.
- Standalone profit after tax was Rs 128.16 lakh on revenue from operations of Rs 32.60 crore.
powered by IRIS

Vilin Bio Med Limited used Rs 68.10 lakh in operating cash in the half-year ended September 30, 2026, despite reporting standalone profit after tax of Rs 128.16 lakh, as inventory and trade receivables absorbed Rs 603.41 lakh. Cash and cash equivalents consequently declined to Rs 21.52 lakh from Rs 146.99 lakh at March 31, 2026.
Know Vilin Bio Med inside out
Results, valuation, peers and who's buying, in one view.
Why did Vilin Bio Med report negative operating cash flow?
Vilin Bio Med reported negative operating cash flow because its Rs 175.93 lakh profit before tax and Rs 20.35 lakh depreciation adjustment were outweighed by a Rs 264.39 lakh adverse working-capital adjustment in the September 2026 half. Net cash flow from operating activities was therefore an outflow of Rs 68.10 lakh, with no interest, dividend or income-tax cash-flow adjustment reported for the period.
The two largest cash uses were a Rs 327.69 lakh increase in inventories and a Rs 275.72 lakh increase in trade receivables. These movements totalled Rs 603.41 lakh, exceeding the reported pre-tax profit by Rs 427.48 lakh. They were partly offset by a Rs 272.78 lakh increase in trade payables, a Rs 62.63 lakh reduction in other current assets and a Rs 18.45 lakh increase in other current liabilities.
The cash-flow statement provides the year ended March 31, 2026 as the comparative period rather than a prior-year half-year. Vilin Bio Med generated Rs 69.80 lakh from operating activities in that year after Rs 87.83 lakh of income-tax payments, compared with the Rs 68.10 lakh operating cash outflow in the September half. The reported half-year therefore showed a different cash outcome from the prior full year as operating assets consumed funds.
How did inventory and receivables change in September 2026?
Vilin Bio Med’s inventory balance rose to Rs 10.4922 crore at September 30, 2026 from Rs 7.2153 crore at March 31, 2026, an increase of Rs 3.2769 crore. The cash-flow statement records a Rs 327.69 lakh working-capital outflow for inventories during the half-year. This balance-sheet movement and cash-flow adjustment both show that the inventory increase used cash.
Trade receivables increased to Rs 18.7134 crore from Rs 15.9562 crore over the same period, a rise of Rs 2.7572 crore. The cash-flow statement records a Rs 275.72 lakh receivables outflow. Inventories and trade receivables together stood at Rs 29.2056 crore at September 30, compared with Rs 23.1715 crore at March 31, 2026.
Other working-capital lines partly moved in the opposite direction. Trade payables other than amounts due to micro, small and medium enterprises, or MSMEs, increased to Rs 6.0828 crore from Rs 3.3550 crore, while other current assets fell to Rs 1.6824 crore from Rs 2.3087 crore. Short-term loans and advances rose to Rs 57.07 lakh from Rs 43.29 lakh, creating a Rs 13.78 lakh cash outflow.
What happened to Vilin Bio Med’s cash balance?
Vilin Bio Med’s cash and cash equivalents fell by Rs 125.47 lakh during the September 2026 half, closing at Rs 21.52 lakh against Rs 146.99 lakh at the beginning of the period. The decline comprised the Rs 68.10 lakh operating outflow, Rs 41.18 lakh used in investing activities and Rs 16.19 lakh used in financing activities.
Investing cash outflow included Rs 39.18 lakh spent on fixed assets and Rs 2.00 lakh used to purchase investments or equity instruments. Property, plant and equipment increased to Rs 3.0534 crore at September 30 from Rs 2.8651 crore at March 31, while non-current investments were Rs 2.00 lakh at the half-year end. The filing does not provide a project-level breakdown of the fixed-asset purchases.
Financing activities used Rs 16.19 lakh, comprising Rs 16.18 lakh of borrowing repayment and Rs 10 of interest paid. In the year ended March 31, 2026, financing activities had produced a Rs 101.26 lakh inflow, including Rs 3.38 crore from issue of shares and security premium, partly offset by Rs 2.3674 crore of borrowing repayment. No share-issue proceeds were reported in the September 2026 half.
Got a follow-up? Ask IRIS
How did Vilin Bio Med’s profit and revenue compare with earlier periods?
Vilin Bio Med reported standalone revenue from operations of Rs 32.60 crore for the half-year ended September 30, 2026, almost unchanged from Rs 32.5990 crore in the half-year ended March 31, 2026. Revenue was higher than Rs 9.6640 crore in the half-year ended September 30, 2025. Total expenses were Rs 30.8414 crore, compared with Rs 29.9531 crore in the immediately preceding half-year and Rs 9.4702 crore a year earlier.
Standalone profit after tax was Rs 128.16 lakh, down from Rs 177.71 lakh in the half-year ended March 31, 2026 but above Rs 15.17 lakh in the half-year ended September 30, 2025. Basic and diluted earnings per equity share were Rs 0.84, compared with Rs 1.26 in the March 2026 half and Rs 0.11 in the September 2025 half.
Cost of materials consumed was Rs 29.0792 crore, compared with Rs 28.6601 crore in the March 2026 half. Employee-benefit expense increased to Rs 89.60 lakh from Rs 55.80 lakh, while other expenses rose to Rs 66.26 lakh from Rs 52.36 lakh. These expense changes accompanied a decline in profit before tax to Rs 175.93 lakh from Rs 264.71 lakh despite broadly unchanged sequential revenue.
What does Vilin Bio Med’s September balance sheet show about funding?
Vilin Bio Med reported total assets of Rs 39.4414 crore at September 30, 2026, up from Rs 34.9422 crore at March 31, 2026. Current assets increased to Rs 31.6739 crore from Rs 27.3830 crore, led by the combined increase in inventory and trade receivables. This occurred while cash and cash equivalents declined by Rs 125.47 lakh.
Shareholders’ funds were Rs 29.6540 crore at September 30, compared with Rs 28.3724 crore at March 31. Share capital was unchanged at Rs 15.25 crore, while reserves and surplus increased to Rs 14.4040 crore from Rs 13.1224 crore. The Rs 1.2816 crore increase in reserves and surplus matches the standalone profit after tax reported for the half-year.
Current liabilities rose to Rs 9.6407 crore from Rs 6.4417 crore. Alongside higher trade payables, other current liabilities increased to Rs 2.2480 crore from Rs 2.0635 crore and short-term provisions increased to Rs 1.2658 crore from Rs 81.73 lakh. Non-current liabilities, described in the statement as deferred tax liabilities net, were Rs 14.67 lakh against Rs 12.81 lakh at March 31.
Conclusion
Vilin Bio Med remained profitable in the half-year ended September 30, 2026, with Rs 128.16 lakh of standalone profit after tax on Rs 32.60 crore of operating revenue. However, the Rs 3.2769 crore inventory increase and Rs 2.7572 crore receivables increase absorbed more cash than pre-tax profit and depreciation generated, resulting in a Rs 68.10 lakh operating cash outflow.
The filing discloses no cash-flow target, working-capital plan or scheduled operating update. The next results will show whether inventory of Rs 10.4922 crore and trade receivables of Rs 18.7134 crore at September 30 are converted into cash, and whether cash and cash equivalents recover from Rs 21.52 lakh.


